Provectus Biopharmaceuti... (QB) Stock Price

0.002115 (4.0%)
Volume 103,290
Bid Price 0.052
Ask Price 0.056
News -
Day High 0.055


52 Week Range


Day Low 0.05222
Company Name Stock Ticker Symbol Market Type
Provectus Biopharmaceuticals Inc (QB) PVCT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.002115 4.0% 0.055 15:53:03
Open Price Low Price High Price Close Price Prev Close
0.0529 0.05222 0.055 0.055 0.052885
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14 103,290 $ 0.052977 $ 5,472 - 0.0421 - 0.0734
Last Trade Time Type Quantity Stock Price Currency
15:52:02 3,600 $ 0.055 USD


Draw Mode:

Provectus Biopharmaceuticals Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 23.07M 419.50M 381.51M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
457.00 $ - - - -

more financials information »

Provectus Biopharmaceuti... (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PVCT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0550.05850.05110.054438480,0220.000.0%
1 Month0.060950.0630.05110.0577397136,559-0.00595-9.76%
3 Months0.0580.0660.04710.0576934143,532-0.003-5.17%
6 Months0.069450.07250.0450.0601945186,463-0.01445-20.81%
1 Year0.069630.07340.04210.0590107249,370-0.01463-21.01%
3 Years0.0670.130.00050.0636273289,397-0.012-17.91%
5 Years0.0290.130.00050.0617754342,2550.02689.66%

Provectus Biopharmaceuti... (QB) Description

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of chemical small molecules called halogenated xanthenes. Intratumoral (aka intralesional) PV-10, the first small molecule autolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic uveal melanoma), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma) and blood cancers (e.g., acute myeloid leukemia). Topical PH-10 is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.

Your Recent History
Provectus ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now